Home > Haematology > ASH 2021 > Acute Lymphoblastic Leukaemia > EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL

EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL

Presented By
Prof. Patrice Chevallier, Nantes University Hospital, France

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Trial
Phase 2, EWALL-INO
Fractionated inotuzumab ozogamicin plus low-intensity chemotherapy was well tolerated and demonstrated high activity as first-line therapy in older patients with CD22-positive, Philadelphia Chromosome-negative (Ph-neg) B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). This was the main primary result of the prospective, multicentre, phase 2 EWALL-INO trial [1]. “The 2-year overall survival rate of BCP-ALL in older patients is approximately 30%,” according to Prof. Patrice Chevallier (Nantes University Hospital, France). “Since BCP-ALL is the most common ALL in older patients, there is a high need for effective therapies. The high expression rate of CD22 in patients with BCP-ALL (>90%) justifies the investigation of inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, in this population.” The current phase 2 EWALL-INO trial (NCT03249870


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on